These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2011 related articles for article (PubMed ID: 23726814)

  • 21. Pre-transplant donor specific antibody and its clinical significance in kidney transplantation.
    Thammanichanond D; Ingsathit A; Mongkolsuk T; Rattanasiri S; Kantachuvesiri S; Sakhonrat C; Leenanupan C; Worawichawongs S; Kitpoka P
    Asian Pac J Allergy Immunol; 2012 Mar; 30(1):48-54. PubMed ID: 22523907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic flow cytometric crossmatch in renal transplantation: a single assay to simultaneously detect antibody binding and cytotoxicity.
    Thammanichanond D; Athimang W; Paisooksantivatana K; Mongkolsuk T; Ingsathit A; Worawichawong S; Kitpoka P; Jirasiritham S; Kantachuvesiri S
    Transplant Proc; 2012 Jan; 44(1):62-5. PubMed ID: 22310580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The results of HLA-incompatible kidney transplantation according to pre-transplant crossmatch tests: Donor-specific antibody as a prominent predictor of acute rejection.
    Kwon H; Kim YH; Kim JY; Choi JY; Shin S; Jung JH; Park SK; Han DJ
    Clin Transplant; 2019 May; 33(5):e13533. PubMed ID: 30864255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection.
    Hirai T; Kohei N; Omoto K; Ishida H; Tanabe K
    Transpl Int; 2012 Sep; 25(9):925-34. PubMed ID: 22764746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation.
    Riethmüller S; Ferrari-Lacraz S; Müller MK; Raptis DA; Hadaya K; Rüsi B; Laube G; Schneiter G; Fehr T; Villard J
    Transplantation; 2010 Jul; 90(2):160-7. PubMed ID: 20658760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor specific antibodies before and after kidney transplant: the University of Colorado Experience.
    Cooper JE; Gralla J; Adebiyi O; Wiseman AC; Chan L
    Clin Transpl; 2013; ():407-12. PubMed ID: 25095536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
    Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
    Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients.
    Guidicelli G; Anies G; Bachelet T; Dubois V; Moreau JF; Merville P; Couzi L; Taupin JL
    Transpl Immunol; 2013 Dec; 29(1-4):17-21. PubMed ID: 24056164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value and cost-effectiveness of different screening strategies for HLA antibodies prior to kidney transplantation.
    Ziemann M; Schönemann C; Bern C; Lachmann N; Nitschke M; Fricke L; Görg S
    Clin Transplant; 2012; 26(4):644-56. PubMed ID: 22432638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
    Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation.
    Morris GP; Phelan DL; Jendrisak MD; Mohanakumar T
    Hum Immunol; 2010 Mar; 71(3):268-73. PubMed ID: 20074605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinically-relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation.
    Salvadé I; Aubert V; Venetz JP; Golshayan D; Saouli AC; Matter M; Rotman S; Pantaleo G; Pascual M
    Hum Immunol; 2016 Jun; 77(6):483-9. PubMed ID: 27085791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement of donor-specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody-mediated rejection.
    Jackups R; Canter C; Sweet SC; Mohanakumar T; Morris GP
    J Clin Apher; 2013 Aug; 28(4):301-8. PubMed ID: 23426730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
    Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.
    Reinsmoen NL; Lai CH; Vo A; Cao K; Ong G; Naim M; Wang Q; Jordan SC
    Transplantation; 2008 Sep; 86(6):820-5. PubMed ID: 18813107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
    Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
    Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch.
    Higgins R; Lowe D; Hathaway M; Williams C; Lam FT; Kashi H; Tan LC; Imray C; Fletcher S; Chen K; Krishnan N; Hamer R; Daga S; Edey M; Zehnder D; Briggs D
    Transplantation; 2011 Oct; 92(8):900-6. PubMed ID: 21968524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients.
    Pavlova YA; Malek I; Honsova E; Netuka I; Sochman J; Lodererova A; Kolesar L; Striz I; Skibova J; Slavcev A
    Tissue Antigens; 2010 Nov; 76(5):380-6. PubMed ID: 20604893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients.
    Schaefer SM; Süsal C; Opelz G; Döhler B; Becker LE; Klein K; Sickmüller S; Waldherr R; Macher-Goeppinger S; Schemmer P; Beimler J; Zeier M; Morath C
    HLA; 2016 Feb; 87(2):89-99. PubMed ID: 26840927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 101.